Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedApr 10, 2026
DataAggregated Company Financials
Companies20
  • 7D-0.06%
  • 3M-33.5%
  • 1Y-35.0%
  • YTD-25.1%

The Healthcare industry has been flat over the last week, but Coloplast has lost 4.9%. Unfortunately though, the industry is down 35% over the past 12 months. As for the next few years, earnings are expected to grow by 4.9% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 10 Apr 2026DKK 1.5tDKK 447.3bDKK 130.0b18x11.3x3.3x
Sun, 08 Mar 2026DKK 1.5tDKK 448.2bDKK 131.1b17.1x11.6x3.4x
Tue, 03 Feb 2026DKK 2.1tDKK 453.6bDKK 136.8b17.8x15.7x4.7x
Thu, 01 Jan 2026DKK 1.9tDKK 453.7bDKK 136.9b17.2x14.2x4.3x
Sat, 29 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.5x14x4.2x
Mon, 27 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.7x14.3x4.5x
Wed, 24 Sep 2025DKK 2.2tDKK 447.1bDKK 141.6b18.9x15.2x4.8x
Fri, 22 Aug 2025DKK 2.1tDKK 444.8bDKK 139.9b29.1x14.7x4.6x
Sun, 20 Jul 2025DKK 2.3tDKK 423.3bDKK 124.5b29.9x18.4x5.4x
Tue, 17 Jun 2025DKK 2.7tDKK 423.4bDKK 124.6b31.2x21.6x6.3x
Thu, 15 May 2025DKK 2.4tDKK 423.4bDKK 124.9b23.3x19x5.6x
Sat, 12 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.9x19x5.6x
Mon, 10 Mar 2025DKK 3.2tDKK 409.5bDKK 121.3b27x26.1x7.7x
Wed, 05 Feb 2025DKK 3.2tDKK 388.1bDKK 111.2b28.6x28.9x8.3x
Fri, 03 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.4x30.2x8.7x
Sun, 01 Dec 2024DKK 3.9tDKK 387.3bDKK 111.3b31.2x35.2x10.1x
Tue, 29 Oct 2024DKK 4.0tDKK 372.2bDKK 107.2b34x37.3x10.7x
Thu, 26 Sep 2024DKK 4.3tDKK 371.9bDKK 107.1b37x40.5x11.7x
Sat, 24 Aug 2024DKK 4.7tDKK 371.6bDKK 107.0b36.6x43.6x12.6x
Mon, 22 Jul 2024DKK 4.6tDKK 355.3bDKK 106.2b35.6x43.3x12.9x
Wed, 19 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.7x46.4x13.9x
Fri, 17 May 2024DKK 4.6tDKK 355.7bDKK 106.8b35.1x43.5x13.1x
Sun, 14 Apr 2024DKK 4.5tDKK 341.3bDKK 99.7b33.5x45.1x13.2x
Tue, 12 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b40x46.3x13.5x
Thu, 08 Feb 2024DKK 4.2tDKK 339.6bDKK 98.7b33.9x42.6x12.4x
Sat, 06 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.3x41.7x11.7x
Mon, 04 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.8x40.3x11.3x
Wed, 01 Nov 2023DKK 3.5tDKK 305.6bDKK 82.3b27.9x42.5x11.4x
Fri, 29 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b32.9x41.8x11.2x
Sun, 27 Aug 2023DKK 3.4tDKK 305.2bDKK 82.1b35x41.2x11.1x
Tue, 25 Jul 2023DKK 3.0tDKK 287.0bDKK 75.5b36.4x39.7x10.4x
Thu, 22 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.1x39.7x10.4x
Sat, 20 May 2023DKK 3.2tDKK 286.5bDKK 75.3b41.9x42x11x
Mon, 17 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b43x46x11.6x
Price to Earnings Ratio

46x


Total Market Cap: DKK 3.2tTotal Earnings: DKK 68.5bTotal Revenue: DKK 272.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 31.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.3x which is lower than its 3-year average PE of 31.6x.
  • The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.93%
Healthcare-0.057%
Biotech1.78%
Pharma0.42%
Healthtech-2.57%
Medical Equipment-4.45%
Life Sciences-5.13%
Healthcare Services-9.29%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 533x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.2% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 241.802.1%
+DKK 21.6b		-42.5%PE10.5x
GMAB GenmabDKK 1.80k2.3%
+DKK 2.5b		46.8%PE18x
ALK B ALK-AbellóDKK 212.203.1%
+DKK 1.4b		50.9%PE39.3x
EMBLA Embla Medical hfDKK 27.652.4%
+DKK 277.7m		3.6%PE22.2x
BAVA Bavarian NordicDKK 197.801.1%
+DKK 162.1m		35.6%PE11.1x

Latest News

BIOPOR
DKK 0.99
BioPorto
7D
11.6%
1Y
-26.0%
COLO B
DKK 432.10
Coloplast
7D
-2.4%
1Y
-37.9%

COLO B: New CEO Appointment Will Support Future Re Rating Potential

The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.
ALK B
DKK 212.20
ALK-Abelló
7D
3.1%
1Y
50.9%

ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption

Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.
SMSMED
DKK 2.96
Scandinavian Medical Solutions
7D
-8.4%
1Y
-31.6%
EMBLA
DKK 27.65
Embla Medical hf
7D
2.4%
1Y
3.6%

EMBLA: Capital Reduction And Buybacks Will Support Future Upside Potential

Analysts have modestly lifted their price target for Embla Medical hf. to DKK 34.0, reflecting slightly updated assumptions around discount rate, revenue growth, profit margin and future P/E.
GMAB
DKK 1,798.50
Genmab
7D
2.3%
1Y
46.8%
DEMANT
DKK 196.20
Demant
7D
0.3%
1Y
-11.8%

DEMANT: Recent Upgrades And 2026 Guidance May Support Re Rating

The updated analyst price target for Demant now sits at DKK 232, up modestly from DKK 232. The small adjustment reflects a mix of recent upgrades and price target cuts as analysts reassess assumptions for discount rates, revenue growth, profit margins and future P/E levels.
ZEAL
DKK 291.80
Zealand Pharma
7D
-2.1%
1Y
-31.8%

ZEAL: Obesity Partnership With Roche And AI Hub Will Drive Future Re Rating

Analysts have sharply reduced price targets on Zealand Pharma, with several firms shifting to more neutral ratings and resetting expectations to a range of around DKK 275 to DKK 460. This reflects more conservative views on petrelintide's role in a competitive obesity market.
GUBRA
DKK 342.00
Gubra
7D
-6.1%
1Y
-9.3%
AMBU B
DKK 65.65
Ambu
7D
-4.9%
1Y
-44.1%

AMBU B: Refined Discount Rate And P/E Expectations Will Support Future Upside

Analysts have lowered their price target on Ambu by DKK 12. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions following recent research updates.
HLUN B
DKK 40.52
H. Lundbeck
7D
-0.6%
1Y
44.7%

HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins

Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.
NOVO B
DKK 241.80
Novo Nordisk
7D
2.1%
1Y
-42.5%

NOVO B: Future Returns Will Rely On Weekly Diabetes And Obesity Treatments

Narrative Update: Novo Nordisk Price Target Shift The analyst price target for Novo Nordisk has been adjusted slightly higher to DKK 309.77 from DKK 309.63. This reflects updated analyst assumptions that incorporate revised revenue growth, profit margin and future P/E inputs.
BAVA
DKK 197.80
Bavarian Nordic
7D
1.1%
1Y
35.6%

BAVA: Expanded Vaccine Pipeline And New Contracts Will Support Higher Future Returns

Analysts have raised their price target on Bavarian Nordic from DKK 244.00 to DKK 280.00. They cite updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that they view as better reflecting the company’s current outlook.
CHEMM
DKK 304.60
ChemoMetec
7D
-1.4%
1Y
-33.5%
MONSO
DKK 0.15
Monsenso
7D
15.4%
1Y
-39.5%
NNIT
DKK 45.50
NNIT
7D
-3.0%
1Y
-31.0%